Skip to Main Content

A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Conditions

Diseases of the Lung | Diseases of the Respiratory Systems

Phase IIB

What is the purpose of this trial?

Brief Summary:

This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of TD139.

  • Trial with
    Galecto Biotech AB
  • Start Date
    11/17/2019
  • End Date
    03/30/2021
Trial Image

For more information about this study, contact:

Donna Carrano

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    12/09/2019
  • Study HIC
    #2000025337